Coordinatore | Probiotics International Limited
Organization address
address: Lopen Head South Petherton contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Sito del progetto | http://www.qualvivo.eu |
Totale costo | 1˙131˙216 € |
EC contributo | 880˙380 € |
Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
Code Call | FP7-SME-2008-1 |
Funding Scheme | BSG-SME |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-07-01 - 2011-06-30 |
# | ||||
---|---|---|---|---|
1 |
Probiotics International Limited
Organization address
address: Lopen Head South Petherton contact info |
UK (Somerset) | coordinator | 171˙951.00 |
2 |
LAVIVO AB
Organization address
address: Bullegummansgata 7 contact info |
SE (Vastra Frolunda) | participant | 428˙758.00 |
3 |
LABORATOIRES LYOCENTRE
Organization address
address: Rue des Freres Lumieres contact info |
FR (ARPAJON SUR CERE) | participant | 243˙611.00 |
4 |
DANISH INNOVATION INSTITUTE A/S
Organization address
address: Diplomvej Bygning 373 contact info |
DK (Kongens Lyngby) | participant | 16˙876.00 |
5 |
CHR. HANSEN A/S
Organization address
address: Boege Alle 10-12 contact info |
DK (HOERSHOLM) | participant | 12˙584.50 |
6 |
SKANE LANS LANDSTING
Organization address
city: KRISTIANSTAD contact info |
SE (KRISTIANSTAD) | participant | 6˙600.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Stress, medications, global travel and an imbalanced diet are having an increasingly adverse effect on the health of the European population derived from weakened immune systems. This manifests itself in the occurrence of serious ailments such as acute infectious diarrhoea (AID), ulcerative colitis (UC), travellers’ diarrhoea (TD) and antibiotic associated diarrhoea (AAD). Specifically, in the case of AAD, it is estimated that between five and 25 per cent of patients experience diarrhoea, including Clostridium difficile associated diarrhoea, as a complication of treatment with antibiotics. The project aims to develop a three-fold Quality Control approach to the development of a probiotic supplement: i) Develop a “Tailor made” unique blend of bacteria, the origin of which has a sound scientific basis and is not based on commercial availability. Each individual bacterial component will be screened for stability (both processing and gut environment), and adhesion to gut mucosa. ii) Develop a “Tailor made” prebiotic “partner” which will ensure the sustainability of the resulting synbiotic blend and to potentially enhance the immunostimulatory and anti inflammatory properties of the synbiotic. iii) Pre-conditioning of the bacterial blend will impart inherent robustness and eliminate the need for the additional (costly) physical and chemical processing required for protection in the gut.'
Development of a Point of Care microfluidic chip unit and self-sampling device for cervical cancer screening and platform technology for Nucleic Acid Detection at the Point of Care
Read More